BeyondSpring is trading 5.8% down at $0.74; no confirmed company-specific announcement explains the October 6 decline.

  • The FDA Fast Track designation and trial-funding transaction were announced September 29, not today.
  • Biotech-sector weakness may be contributing: XBI was down 2.50% during the session while major U.S. indexes were higher. This is supporting context, not proof of BeyondSpring’s specific cause.